STEAP1 and prostate carcinoma: Notwithstanding, Sandra et al. demonstrated that knockdown of STEAP1 by siRNA reduces viability and proliferation and downregulates survival pathways (such as AKT and ERK signaling) of LNCaP and C4-2B prostate cancer cells [279].